Anamorelin Efficacy in Non–Small‐Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2

ABSTRACT Background Cancer cachexia presents a significant challenge, but the ghrelin agonist anamorelin shows promise as a potential treatment. This study examined whether the baseline systemic inflammatory response (SIR) (measured by the modified Glasgow Prognostic Score [mGPS]), low BMI or greate...

Descripción completa

Detalles Bibliográficos

Autores principales:	Barry J. A. Laird, Richard Skipworth, Philip D. Bonomi, Marie Fallon, Stein Kaasa, Ruben Giorgino, Donald C. McMillan, David C. Currow
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2025-02-01
Colección:	Journal of Cachexia, Sarcopenia and Muscle
Materias:	cachexia cancer modified Glasgow Prognostic Score ROMANA 1 ROMANA 2 systemic inflammatory response
Acceso en línea:	https://doi.org/10.1002/jcsm.13732
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!